CHRM1 and Alzheimer disease: Recently, MK‐7622, a first‐in‐class high cooperative M1R PAM,28, 29 has shown no effect on cognition as adjunctive therapy with AChEIs in patients with AD.30 In the present study, to gain more insight into the differences between low and high cooperative M1R PAMs, we characterized the pharmacological profile of the novel low cooperative M1R PAM T‐495 using MK‐7622 as a control M1R PAM with a higher cooperative value.